RNA therapeutics

State of the art (2026)

RNA medicines are a mainstream drug class with substantial sales. Alnylam's Givlaari, Oxlumo and Amvuttra all use GalNAc, a sugar tag that carries the drug into liver cells. So does Leqvio, which uses Alnylam's technology and is sold by Novartis under licence. Alnylam's second-quarter 2026 report showed growing sales of its TTR medicines and new Phase 2 programmes. The open work is in common chronic diseases and in reaching tissues other than the liver. Success in one disease or with one delivery method does not carry over automatically to the next. Delivery, safety and effectiveness have to be shown for each product.

Six RNA therapies projected above $1B by 2030 - the category is commercial scale

RNA therapeutics has commercially proven across siRNA / RNAi (Alnylam: Onpattro, Givlaari, Oxlumo, Amvuttra; Novartis Leqvio with inclisiran), antisense oligonucleotides (Ionis: Spinraza via Biogen, Tegsedi, Waylivra, Tryngolza approved December 2024, Wainua via AstraZeneca), and mRNA (Moderna and Pfizer-BioNTech COVID-19 plus pipeline). Six therapies are projected above $1B annual revenue by 2030: Alnylam Amvuttra (ATTR amyloidosis), Novartis Leqvio (LDL cholesterol), Astellas Izervay (geographic atrophy), Biogen Spinraza (SMA), Geron Rytelo (myelodysplastic syndromes), AstraZeneca Wainua (transthyretin amyloidosis). The structural progression: from rare-disease orphan-drug niches (where Alnylam and Ionis built initial commercial proof) into large chronic-disease populations (cardiovascular, dyslipidemia, neurodegenerative). The category is no longer 'novel therapeutic modality' - it is a mainstream pharma class with established pricing, reimbursement, and manufacturing infrastructure.

Alnylam zilebesiran ZENITH CVOT is the largest single RNA therapeutic bet

Alnylam and Roche partnered on zilebesiran - a twice-yearly subcutaneous siRNA targeting angiotensinogen for uncontrolled hypertension - and advanced it into the global ZENITH Phase 3 cardiovascular outcomes trial in October 2025. ZENITH enrols approximately 11,000 patients across 35 countries, dosing 300 mg every six months versus placebo, with the primary endpoint being reduction in the composite of cardiovascular death, non-fatal MI, non-fatal stroke, or heart failure events. Phase 2 KARDIA-3 results published in 2025-2026 showed placebo-adjusted systolic BP reduction of -5.0 mmHg at month 3 and -3.9 mmHg at month 6 (sustained at -8 mmHg+ in baseline office SBP ≥140 cohort). If ZENITH reads out positive (CVOT timelines push readout to 2028-2030), zilebesiran becomes the first twice-yearly RNA therapy for a chronic non-rare cardiovascular indication - an addressable population of 1B+ adults globally with hypertension, of whom approximately half are uncontrolled. The largest single program-level bet in the RNA therapeutics category.

mRNA cancer vaccines move from melanoma proof-of-concept toward first approvals

The Moderna mRNA-4157 (V940) plus Merck pembrolizumab combination for resected high-risk melanoma has continued to show sustained 3-year recurrence-free survival benefit over pembrolizumab monotherapy. Phase 3 program global expansion is underway with regulatory submissions anticipated in 2026 and first approvals targeted late 2026-2027. The oncology pipeline beyond melanoma is broadening: V940 in non-small-cell lung cancer Phase 3 (in progress); BioNTech BNT122 (autogene cevumeran) in pancreatic and colorectal Phase 2-3; competing platforms (Genevant, Cure-Genetics, Replicate) entering clinical phase. The personalised-neoantigen-vaccine thesis depends on manufacturing economics - producing a patient-specific RNA vaccine on a 6-8 week clinical timeline is the operational test that differentiates Moderna from competitors that have not yet built dedicated manufacturing. First approval converts the category from research to commercial.